Here, we also observed that ER−/HER2+ tumours tended to respond better to neoadjuvant therapy with an odds ratio of ~6.97 for ER-neg versus ER+ in a predictive model of pCR along with age at diagnosis and lymphocyte density. This evidence concerns the gene ERBB2 and neoplasm.